United States-based Pfizer is opening a new manufacturing facility in Andover, Massachusetts, it was reported yesterday.
The facility covers a 175,000 square-foot area. It accommodates commercial manufacturing and product development functions for the development and production of complex biologics and vaccines. The site will offer 75 new jobs for the Andover area economy, adding to the around 2,000 staff currently based in Massachusetts.
The newly opened Andover Clinical Manufacturing Facility will expand the capacity for Pfizer's BioTherapeutics Pharmaceutical Sciences organization to manufacture clinical supplies. The company's ACMF investment is more than USD200m and includes five independent manufacturing suites, with more than 50 projects currently in development.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results